(Q36423497)

14 August 2017

1 reference

title

Acute exacerbation of chronic bronchitis: expanding short-course therapy (English)

1 reference

14 August 2017

1 reference

Fernando J Martinez

1

1 reference

14 August 2017

publication date

1 December 2005

1 reference

International Journal of Antimicrobial Agents

14 August 2017

published in

1 reference

14 August 2017

volume

26 Suppl 3

1 reference

14 August 2017

page(s)

S156-63

1 reference

The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

COPD exacerbations: the importance of a standard definition

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Toward a consensus definition for COPD exacerbations

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Time course of recovery of health status following an infective exacerbation of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Treatment cost of acute exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Pharmacoeconomic Evaluation of Acute Exacerbations of Chronic Bronchitis and COPD

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Acute exacerbations of chronic bronchitis: what role for the new fluoroquinolones?

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

The spectrum of acute bronchitis. Using baseline factors to guide empirical therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Use of the protected specimen brush technique in 54 mechanically ventilated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Nontypeable Haemophilus influenzae in the lower respiratory tract of patients with chronic bronchitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

New strains of bacteria and exacerbations of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Strain-specific immune response to Haemophilus influenzae in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease and immune response

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Infectious exacerbations of chronic obstructive pulmonary disease associated with respiratory viruses and non-typeable Haemophilus influenzae.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Haemophilus influenzae from patients with chronic obstructive pulmonary disease exacerbation induce more inflammation than colonizers

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Relationship Between Bacterial Flora in Sputum and Functional Impairment in Patients With Acute Exacerbations of COPD

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Bacterial infection in exacerbated COPD with changes in sputum characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Acute bronchitis: state of the art diagnosis and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Antibiotic treatment and baseline severity of disease in acute exacerbations of chronic bronchitis: a re-evaluation of previously published data of a placebo-controlled randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Canadian guidelines for the management of acute exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Drug‐Resistant Pneumococcal Pneumonia: Clinical Relevance and Related Factors

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Streptococcus pneumoniaeBacteremia: Duration of Previous Antibiotic Use and Association with Penicillin Resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Predicting antimicrobial resistance in invasive pneumococcal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Acute exacerbations of chronic bronchitis: new developments concerning microbiology and pathophysiology--impact on approaches to risk stratification and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Epidemiology and Treatment of Chronic Bronchitis and Its Exacerbations

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

No more equivalence trials for antibiotics in exacerbations of COPD, please

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Acute exacerbation of chronic bronchitis: disease-specific issues that influence the cost-effectiveness of antimicrobial therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

The infection-free interval: its use in evaluating antimicrobial treatment of acute exacerbation of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Clinical implications of macrolide therapy in chronic sinopulmonary diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Levofloxacin versus clarithromycin in COPD exacerbation: focus on exacerbation-free interval

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Randomized, double-blind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Effect of Various Antimicrobial Regimens on the Clinical Course of Exacerbations of Chronic Bronchitis and Chronic Obstructive Pulmonary Disease in Primary Care

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Efficacy and safety of azithromycin vs levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB).

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Oral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999--2000, including a comparison of resistance rates since 1994--1995.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: antimicrobial susceptibility patterns from the SENTRY antimicrobial Surveillance Program (United States and Canada, 1997)

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Increased antibiotic resistance in respiratory tract pathogens: PROTEKT US--an update

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Quinolone-resistant Haemophilus influenzae in a long-term care facility: clinical and molecular epidemiology

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Regulatory effects of macrolides on bacterial virulence: potential role as quorum-sensing inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Azithromycin exhibits bactericidal effects on Pseudomonas aeruginosa through interaction with the outer membrane

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Macrolides in the treatment of asthma and cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Immunomodulatory effects of macrolides in the lung: lessons from in-vitro and in-vivo models

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: ciprofloxacin 750 mg b.i.d. versus clarithromycin 500 mg b.i.d. Bronchitis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2805%2980322-X

7 January 2021

10.1016/S0924-8579(05)80322-X

Identifiers

DOI

1 reference

14 August 2017

1 reference